1. A method of treating or preventing hot flashes in a patient comprising administering to the patient in need of such treatment or prevention a therapeutically effective amount of a prodrug of a GABA analog, or a pharmaceutically acceptable salt, hydrate or solvate thereof.
2. A method of treating or preventing hot flashes in a patient comprising administering to the patient in need of such treatment or prevention a pharmaceutical composition comprising a therapeutically effective amount of a prodrug of a GABA analog, or a pharmaceutically acceptable salt, hydrate or solvate thereof and a pharmaceutically acceptable vehicle.
3. The method of claim 1 or claim 2, wherein the GABA analog is gabapentin or pregabalin.
4 The method of claim 3, wherein the GABA analog is administered in an amount of between about 10 mg to about 5000 mg per day.
5. The method of claim 1, wherein the patient is a female patient.
6. The method of claim 5, wherein the female patient is postmenopausal.
7. The method of claim 6, wherein menopause is drug induced or surgically induced.
8. The method of claim 1, wherein the patient is a male patient.
9. The method of claim 5 or claim 8, wherein the hot flashes are drug-induced.
10. The method of claim 1 or claim 2, wherein the prodrug is administered orally, parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneally, intranasally instillationally, intracavitarally or intravesical instillationally, intraocularly, intraarterially, intralesionally, by implantation or by application to mucous membranes.
11. The method of claim 1 or claim 2, wherein the prodrug is administered orally.
12. The method of claim 1 or claim 2, comprising administering the prodrug in a sustained release oral dosage form.
13. The method of claim 12, wherein the dosage form releases the prodrug gradually over a period of at least about 6 hours after swallowing the dosage form, thereby providing a therapeutic concentration of a GABA analog in the plasma of the patient.
14. The method of claim 12, wherein the dosage form is an osmotic dosage form, a prodrug-releasing polymer, a prodrug-releasing lipid, a prodrug-releasing wax, tiny timed-release pills or prodrug releasing beads.
15. The method of claim 1 or claim 2, wherein the prodrug of a GABA analog has the structure of Formula (I):
18
or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein:
n is 0 or 1;
Y is O or S;
R16 is hydrogen, alkyl or substituted alkyl;
R2 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, acyl, substituted acyl, alkoxycarbonyl, substituted alkoxycarbonyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, or optionally, R2 and R16 together with the atoms to which they are attached form a cycloheteroalkyl or substituted cycloheteroalkyl ring;
R3 and R6 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl and substituted heteroarylalkyl;
R4 and R5 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl and substituted heteroarylalkyl or optionally, R4 and R5 together with the carbon atom to which they are attached form a cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl or bridged cycloalkyl ring;
R7 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl and substituted heteroarylalkyl;
R13 and R14 are each independently hydrogen, alkyl, substituted alkyl, alkoxycarbonyl, substituted alkoxycarbonyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl or optionally, R13 and R14 together with the carbon atom to which they are attached form a cycloalkyl, substituted cycloalkyl, cycloheteroalkyl or substituted cycloheteroalkyl ring; and
R25 is selected from the group consisting of acyl, substituted acyl, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl and substituted heteroarylalkyl.
16. The method of claim 15, wherein the prodrug of a GABA analog has the structure of Formulae (II) or (III):
19
17. The method of claim 16, wherein n is 0.
18. The method of claim 16, wherein n is 1, R16 is hydrogen and R2 is selected from the group consisting of hydrogen, methyl, 2-propyl, 2-butyl, isobutyl, tert-butyl, cyclopentyl, cyclohexyl, phenyl, benzyl, 4-hydroxybenzyl, 4-imidazolylmethyl, 3-indolylmethyl, CH2OH, CH(OH)CH3, CH2CO2H, CH2CH2CO2H, CH2CONH2, CH2CH2CONH2, CH2CH2SCH3, CH2SH, CH2(CH2)3NH2 and CH2CH2CH2NHC(NH)NH2.
19. The method of claim 17, wherein R25 is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and sec-butyl, R13 is methyl and R14 is hydrogen.
20. The method of claim 17, wherein R25 is isopropyl, R13 is methyl and R14 is hydrogen.
21. A pharmaceutical composition for treating a patient suffering from hot flashes comprising a therapeutically effective amount of a prodrug of a GABA analog or a pharmaceutically acceptable salt, hydrate or solvate thereof, and a pharmaceutically acceptable vehicle.
22. A pharmaceutical composition for preventing hot flashes in a patient at risk of hot flashes comprising a therapeutically effective amount of a prodrug of a GABA analog or a pharmaceutically acceptable salt, hydrate or solvate thereof and a pharmaceutically acceptable vehicle.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A furniture panel having a tackable surface, the furniture panel comprising:
a rigid fiberglass core layer;
a tackable foam layer affixed to the rigid core layer; and
a covering material affixed to the rigid core layer that at least partially covers a tackable surface of the foam layer.
2. The furniture panel of claim 1, wherein the tackable foam layer comprises a cross-linked, closed-cell, polyolefin foam.
3. The furniture panel of claim 2, wherein the foam is a polypropylene foam.
4. The furniture panel of claim 2, wherein the tackable foam layer has a thickness of about 1 to 6 mm, a density of about 1.5 to 4 lbft3, and a compressive strength of more than about 0.3 kgcm2.
5. The furniture panel of claim 4, wherein the tackable foam layer has a thickness of about 2.8 to 3.4 mm.
6. The furniture panel of claim 4, wherein the tackable foam layer has a density of about 1.7 to 2.3 lbft3.
7. The furniture panel of claim 4, wherein the tackable foam layer has a gel fraction of about 30-40%.
8. The furniture panel of claim 4, wherein the tackable foam layer has a thickness of about 2.8 to 3.4 mm, a density of about 1.7 to 2.3 lbft3, and a gel fraction of about 30-40%.
9. The furniture panel of claim 1, wherein the tackable foam layer is adhered to the rigid core layer via a pressure sensitive adhesive.
10. The furniture panel of claim of claim 1, wherein the tackable foam layer has a fire rating in accordance with ASTME 84 Class I.
11. The furniture panel of claim 1, wherein the covering is wrapped around the tackable foam layer and the rigid core layer sufficiently tightly to affix the tackable foam layer to the rigid core layer via friction between the tackable foam layer and the rigid core layer.
12. The furniture panel of claim 1, further comprising:
a frame that receives the tackable foam layer and the rigid core layer such that the tackable foam layer is affixed to the rigid core layer.
13. A substrate having a tackable surface, comprising:
a tackable foam sheet; and
a pressure sensitive adhesive layer affixed to the tackable foam sheet, the pressure sensitive adhesive layer comprising a pressure sensitive adhesive and a release backing.
14. A substrate having a tackable surface, the substrate comprising:
a rigid fiberglass core layer; and
a tackable foam layer affixed to the rigid fiberglass core layer.
15. The substrate of claim 14, wherein the tackable foam layer comprises a cross-linked, closed-cell, polyolefin foam.
16. The substrate of claim 15, wherein the foam is a polypropylene foam.
17. The substrate of claim 16, wherein the tackable foam layer has a thickness of about 1 to 6 mm, a density of about 1.5 to 4 lbft3, and a compressive strength of more than about 0.3 kgcm2.
18. The substrate of claim 17, wherein the tackable foam layer has a thickness of about 2.8 to 3.4 mm, a density of about 1.7 to 2.3 lbft3, and a gel fraction of about 30-40%.
19. The substrate of claim 14, wherein the tackable foam layer is adhered to the rigid core layer via a pressure sensitive adhesive.
20. The substrate of claim 14, wherein the tackable foam layer has a fire rating in accordance with ASTME 84 Class I.